Pharmaniaga Berhad

Total Valuation

Pharmaniaga Berhad carries a market capitalization of 1.67B, placing it among publicly traded companies globally. Its enterprise value stands at 1.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pharmaniaga Berhad currently has 6.56B shares outstanding.

Valuation Ratios

Pharmaniaga Berhad trades at a trailing price-to-earnings ratio of 18.49. The price-to-sales ratio is 0.23, and the price-to-book ratio stands at 3.83.

Enterprise Valuation

On an enterprise value basis, Pharmaniaga Berhad trades at an EV/EBITDA multiple of 12.39 and an EV/FCF ratio of 20.26. The EV/Sales ratio of 0.38 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.39 provides insight into valuation relative to core operating earnings.

Financial Position

Pharmaniaga Berhad maintains a current ratio of 0.92, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 163.39, indicating elevated leverage, while an interest coverage ratio of 2.29 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Pharmaniaga Berhad has paid 23.02M in income taxes, reflecting an effective tax rate of 30.43.

Stock Price Statistics

Pharmaniaga Berhad's stock has gained approximately 2% over the past 52 weeks. The 50-day moving average sits at 0.25, while the 200-day moving average is 0.26.

Income Statement

Over the trailing twelve months, Pharmaniaga Berhad generated 4.05B in revenue and converted that into 50.40M in net income, yielding earnings per share of 0.01. EBITDA reached 124.20M, while operating income came in at 124.20M.

Balance Sheet

Pharmaniaga Berhad holds 217.30M in cash and equivalents against 799.81M in total debt, resulting in a net debt position of 579.44M. Total book value stands at 243.43M, with working capital of -140.86M providing operational flexibility.

Cash Flow

After subtracting -38.33M in capital expenditures, free cash flow totaled -38.33M - equivalent to -0.01 per share.

Margins

Pharmaniaga Berhad operates with a gross margin of 10.15, reflecting its pricing power and cost economics. The operating margin of 3.07 and net profit margin of 1.24 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Pharmaniaga Berhad's most recent stock split took place on June 8, 2026 with a 5:1 split ratio.

Scores

Pharmaniaga Berhad posts an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.